VYNE - VYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy

VYNE Therapeutics (VYNE +7.3%) announced positive efficacy results from the Phase 1b segment of an early-to-mid stage trial evaluating FMX114 to treat mild-to-moderate atopic dermatitis (AD). The company said at week 2, FMX114 showed statistically significant reduction in both absolute and percent change in atopic dermatitis severity index score compared to vehicle gel. The treatment also reduced pruritus or itching compared to vehicle. FMX114 is a gel formulation of tofacitinib and fingolimod that is designed to address inflammation in AD.  The Phase 1b segment enrolled four subjects and the Phase 2a segment of the study is expected to enroll up to 25 subjects, the company said. It expects Phase 2a safety and efficacy results in the second quarter.

For further details see:

VYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy